Could Merck’s COVID Pill Create New, More Evasive COVID-19 Variants?

The COVID-19 variant names are becoming longer. The current version is omicron XBB.1.5. It is responsible for a spike in New York City hospitalizations in December. This is now happening throughout the Northeast. This is also the most vaccinated region in the country.

Eric Topol (executive vice president of the Research Department of Molecular Medicine, Scripps Institute), found that XBB.1.5 is susceptible to immune escape and has a distinct advantage over the BQ.1 dominant omicron. A Cell study that revealed all monoclonal antibody lines, including Evusheld are rendered ineffective by the BQ or XBB lineages has more great news. Evusheld was administered to immunocompromised patients in order to prevent infection.

Researchers are not able to explain why these new variants do not trigger the immune response.

Finally, we discovered that spikes of XBB and BQ subvariants had a similar binding affinity to hACE2 to their predecessors (Figure 5,). This suggests that the recent growth advantage of these subvariants may be due to other factors. Their extreme anti-evasion abilities may be the most important, particularly considering the large herd immunity that has been built up over the past three years due to vaccinations and infections.

The pandemic response is not working. We are still fighting a virus that is constantly evolving three years later. Research is showing that repeated mRNA vaccinations might not work and may even cause harm. Recent Wall Street Journal articles suggest that vaccines could be contributing to continued variant development.

These headlines are from 2021 when dissident doctors such as Dr. Peter McCullough warned of the dangers of turning vaccination into an epidemic. He stated that “By pushing mass vaccinations, governments have created evolutionary pressures for SARS-CoV-2. People warned us about this.” Gia Vanderburgh and Dr. Luke Montie warned us about this. “Don’t do it, don’t vaccinate to a pandemic because there is a high prevalence virus.”

At that time, the fear was that more deadly variants could be created by continued vaccination. This has not been proven to be true. Mass vaccination might lead to a new variant formation. However, patients over 70 still require hospitalizations and the death rate is not increasing exponentially with hospitalizations. Some people say that we have been fortunate, but the risk is still there.

Merck’s antiviral drug molnupiravir has been revealed to be a potential source of new virulent variants. SARS-CoV-2’s replication ability is impaired by Molnupiravir. This is done by causing mutations in the virus’s genome. That’s right, the drug that cures COVID causes COVID to mutate.

This should not be an issue for healthy people. Through phagocytic functions, their immune system removes damaged cells and viruses. These are caused by macrophages, cells that ingest and destroy the foreign substance, or impaired cells. A new study has shown that mutated cells can survive and change in chronically ill patients and those with compromised immune systems.

We discovered a lot of low-frequency mutations (20) in patients within days of treatment with Molnupiravir. These new mutations may persist and in some cases were 21 fixed in virus populations. The drug caused new mutations to the virus’ 22 spike protein. It also affected the amino acid 23 sequences in patients who were treated. This antiviral, which is commonly used in immunocompromised patients can supercharge viral 24 evolution’ and potentially generate new variants. It could also prolong the pandemic by 25.

This seems to be a question that remains unanswered and must be addressed quickly. A large, randomized study conducted in the U.K. showed that the drug did little to reduce the number of deaths or hospitalizations among COVID-infected adults. FDA should immediately revoke the emergency use authorization (EUA) because it failed to provide clinical benefits and is suspected of creating variants.

Outpatient care for high-risk patients is also affected by the drug’s inability to work. Paxlovid by Pfizer has 236 major interactions and 359 minor. People with high cholesterol, diabetes, and kidney disease may experience severe side effects. These side effects can be a major barrier to prescribing to high-risk patients, who are more likely than others to have multiple prescriptions.

The time has come for “experts” and other medical professionals to listen to dissident doctors and to seriously consider their suggestions for multi-drug therapy. Nearly every American knows someone who has received all the recommended vaccines. Many Americans also know someone who used Telemed to obtain generic medication like ivermectin and steroids. It’s time to recognize that the former is not better off than those in the latter group and find a new way.